RANCHO CUCAMONGA, Calif. , June 24, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, will be presenting at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 2:40 p.m.
RANCHO CUCAMONGA, Calif. , June 19, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) today announced that it has entered into a settlement agreement (the “Settlement Agreement”) with Momenta Pharmaceuticals Inc. and Sandoz Inc. , (collectively, “Momenta/Sandoz”).
RANCHO CUCAMONGA, Calif. , June 14, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, will be presenting at the Raymond James Life Sciences and MedTech Healthcare Conference on Wednesday, June 19, 2019 at 4:10 p.m.
RANCHO CUCAMONGA, Calif. , May 31, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President and Bill Peters , CFO, will be presenting at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 8:30 a.m.
RANCHO CUCAMONGA, Calif. , May 10, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President and Bill Peters , CFO, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 at 3:40 p.m.
Reports Net Revenues of $79.8 Million for the Three Months Ended March 31, 2019 RANCHO CUCAMONGA, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2019 .
RANCHO CUCAMONGA, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2019 ended March 31, 2019 , after the market closes on Thursday, May 9, 2019 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , March 19, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration ( FDA ) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple
Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018 RANCHO CUCAMONGA, Calif. , March 12, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31,
RANCHO CUCAMONGA, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2018 ended December 31, 2018 , after the market closes on Tuesday, March 12, 2019 , and will hold a conference call
